Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Bristol Myers Squibb Co would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments and shield itself from competition posed by Merck & Co’s Keytruda on its for its cancer immunotherapy, Opdivo.
The deal gives Bristol Myers, which acquired pharmaceutical company Celgene last year for $74 billion, access to Myokardia’s lead heart drug candidate with blockbuster potential, mavacamten.
According to David Nierengarten, a Wedbush analyst, mavacamten is expected to be a “multi-billion dollar asset” as sales estimates for the treatment of obstructive hypertrophic cardiomyopathy (HCM) is expected to reach about $2.5 billion by 2026.
Hypertrophic cardiomyopathy is estimated to affect one in every 500 people globally.
MyoKardia expects to submit a marketing application to the US health regulator for mavacamten as an obstructive HCM treatment in the first quarter of 2021.
Bristol Myers' portfolio of heart drugs includes blood thinner Eliquis, which made up about 21 percent of the company’s total sales in its latest reported quarter.
